• Room 0G.003 - H.S.B

    United Kingdom

19992024

Research activity per year

Personal profile

Other

Professor Manuel Salto-Tellez (MD-LMS, FRCPath, FRCPI) is the Chair of Molecular Pathology at Queen’s University Belfast, Clinical Consultant Pathologist at the Belfast Health and Social Care Trust and Deputy Director of the Centre for Cancer Research and Cell Biology.

PERSONAL INFORMATION (degrees)

August 1991

Degree (LMS, MD equivalent): Título de Licenciado en Medicina y Cirugía,

October 1998

MRCPath:                    

February 2006

FRCPath                     

December 2013

FRCPI – 48435                        

December 2001

Mol Path Fellowship:  

April 1999

Certificate of Completion of Specialist Training (UK)             

1992

General Medical Council Registration Number (UK): 3624504

1999

Singapore Medical Council Registration Number: 08697E

 

Member of the Royal College of Pathologists: 070761X/ME

 

EDUCATION - Medical Schools (in the context of the ERASMUS Programme)

1984-88

University of Oviedo, Spain;

1988-90

R-W Technischen Hochschule Aachen, Germany;

1990-91

The Royal University of Leiden, The Netherlands.

 

PREVIOUS POSTS (in brief chronological order)

1992 to 2002

Trainee in Pathology at the University of Edinburgh (Royal Infirmary) and the Northwick Park & St. Mark’s Hospitals in London; Fellow in Diagnostic Molecular Pathology at UPENN (USA)

1999 - 2011:

Assistant and Associate Professor, National University of Singapore (NUS). From 2004 - Sr. Research Scientist at the NUS Cancer Science Institute

1999 - 2011:

Consultant and Senior Consultant, Department of Pathology, National University Hospital (NUH), Singapore. Director, Diagnostic Molecular Oncology Centre, NUH

2007 - 2010:

Assist. Dean & Vice-dean for Research, NUS. Head of Clinical Science Research at the National University Health System (NUHS)

2011 to 2014:

Visiting Professor, Department of Pathology & Cancer Science Institute, NUS 

March 2011 to date:

Chair and Professor of Molecular Pathology, Centre for Cancer Research and Cell Biology (CCRCB); School of Medicine, Dentistry and Biomedical Sciences (SMDBS), Queen’s University Belfast (QUB), United Kingdom

March 2011 to date:

Clinical Consultant, Belfast Health and Social Care Trust, UK

July 2012 to date:

Deputy Director, CCRCB; SMDBS, QUB, UK

May 2014 to date:

Associate member of the Cancer Science Institute, NUS

July 2016 to date:

Clinical Director, Molecular Diagnostics, Northern Ireland remit

 

COMMITTEE MEMBERSHIP (selection)

August 2011-14:

Member of the Interspecialty Committee on Molecular Pathology in the Royal College of Pathologists of Great Britain and Ireland

Since March 2012:

Member of the Colorectal Group of the National Cancer Research Institute

Novem 2012-17:

Member of the Molecular Pathology Committee of the Association of Clinical Pathology

March 2013-16:

Member of the Ex. Group of the Confederation of Cancer Biobanks, National Cancer Research Institute

Since June 2013:

Member of the Cancer Research UK Biomarker Expert Review Panel.

Since April 2014:

ECMC Cellular and Molecular Pathology (CM-Path) Network Group

Since Decem 2014:

Member of the UKNEQAS Committee for DNA Quality

Since Novem 2014:

Member of the Molecular Pathology Committee of Genomics England

Since Decem 2014:

Member of the Genomics England GCIPs on CRC and data interpretation

Since August 2015:

Member of the Wales Cancer Research Centre’s External Advisory Board

Since July 2016:

Member of the Main Committee of the Pathological Society of GB & Ireland

Since 2016:

Member of the Cancer Research UK New Agents Committee

July 2016:

Member of the Independent Selection Panel for applications for NIHR funding and designation for Clinical Research Facilities for early translational research (Department of Health)

January 2017

Member of the NIHR Senior Investigators Appointment Panel (Department of Health)

 

RESEARCH GRANTS (selection) – From a total lifetime to date of £7.9M

In Singapore (selection, from a total of S$5.17M - 1£ = 2.2 Singapore $)

Singapore Cancer Syndicate          April 2004 – March 2005: S$275,000

April 2005 – March 2008: S$1,890,000

April 2006 – March 2009: S$1,200,000

July 2008 – July 2011: S$1,005,000

 

In Queen’s University Belfast (from £4.9M of active funding, selection)          Project Title

R1089CNR - Medical Research Council - £163,015

Central Importance of CXCL8 to Inflammation - Promoted Prostate Cancer Progression

R2116CNR - Prostate Cancer UK - £273,017

Movember Centre of Excellence

R3511CNR - Invest NI - £359,272

Establishment of an Intergrated Almac-QUB Drug Discovery Unit at QUB

CRUK - £3,900,000 £

CR-UK Accelerator Award

Pending final confirmation:

Centre of Excellence in Mol Pathology £10,000,000

 

AWARDS AND INTERNATIONAL LEADERSHIP (strict selection)

Awards (selection)

November 1990,

Erasmus Prize of the European Community;

2003

Courage Star by the Courage Fund. This was in recognition to the work developed during the Severe Acute Respiratory Syndrome (SARS) crisis that affected (primarily) the South-east of Asia in 2003;

2005

World Scientists Forum International Award in the field of Onco-Cytology by the International Research Promotion Council (IRPC);

28-29 March 2008

Silver frame in recognition to research in the area of gastrointestinal diseases, presented at the 13th Annual Helenic Helicobacter Pylori Congress, Athens

March 10-11 2010

Keynote Speaker at the 6th Annual Tucson Symposium: Targeted Therapeutics: Leading the Global Paradigm Shift for Pathology, Arizona

7-10 October 2011

Keynote  Speaker at the 41st annual Scientific Meeting of the Australian Society of Cytology. Molecular Biology for the Cytologists, Perth

14 February 2014

Key note speaker at the 32nd Annual Symposium of the Faculty of Pathology of the Royal College of Physicians of Ireland. Integrated Molecular Tissue Pathology.

14-15 March 2016

Leading member of the Advisory Panel to the Division of Cancer Epidemiology and Genomics on Molecular Pathology, NCI/NIH,  (Drs. Stephen Chanok and Montserrat Garcia-Closas)

March-April 2016

Reviewer to the Molecular Pathology Programme at the Ontario Institute of Cancer Research, Canada, (Dr. Thomas J Hudson, President and Scientific Director)

 

Invitations to meetings (strict selection, only since 2010)

2010

24-25 April 2010 

Speaker at the “2010 AstraZeneca Asia Pacific Oncology Summit” - EGFR Mutation Testing, in Taipei, Taiwan.

16-20 May 2010

Invited speaker at the 17th International Congress of Cytology (International Academy of Cytology) to deliver the lecture “Molecular Cytopathology and Personalised Medicine” at the International Conference Centre in Edinburgh, UK, – ACTA CYTOLOGICA  54,3:385-85 2010

June 9-10 2010 

Invited Speaker at the 3rd InterAcademy Medical Panel (IAMP) and General Assembly meeting - “Molecular Diagnostics in Cancer and Implications for the Developing World”, in Kuala Lumpur, Malaysia,

4-5 Septem 2010

Invited Speaker and Guest of Honour at the 2010 Annual Meeting of the Sri Lankan Society of Pathology to deliver several lectures, workshops and speeches, at Kandy, Sri Lanka,

October 1-3 2010

Invited speaker (Plenary Speaker, inaugural session) at the 2010 Annual Scientific Congress of the Malaysian Oncological Society - Role of Pathologist in Personalized Cancer Treatment, at Kota Bharu, Kelantan, Malaysia,

23 October 2010

Invited Speaker at the 8th Meeting of the Association of Directors of Pathology of China - Molecular Pathology, Targeted Therapeutics and the Future of Pathology, Shanghai Everbright Convention & Exhibition Center, China,

Novem 9–11 2010

Invited speaker at the International Conference in Laboratory Medicine at the Sultan Qaboos University, Muscat (Oman): “Molecular Pathology – A hospital based platform for Translational Research”

2011

May 9-10 2011

Invited Speaker by the The Western Australian Clinical Oncology Group - “The Future of Personalized Medicine from a Diagnostic and Therapeutic Perspective”, “Histopathology, Molecular Diagnostics and Therapeutic Pathology - challenges and opportunities” and “Tissue-based Translational Research”, Perth (Australia)

Septem 7-8 2011

2nd Meeting of the Society for Translational Oncology / 3rd CCRCB International Cancer Symposium: EGFR mutation analysis: a paradigm for the future of therapeutic pathology and personalized medicine. Belfast 

2012

8-10 March 2012

Invited Speaker at Coloproctology 2012, 10th annual meeting of the Malaysian Society of Colorectal Surgeons - “Histopathological assessment of rectal cancer resection specimens”, “Introduction to biopsy interpretation” and  “Molecular diagnostics of GIT pathology”, as well as the workshop “Colorectal Pathology”, in Kuching, Sarawak

18 April 2012

Invited speaker at the session - The Importance of Molecular Testing in Non-Small Cell Lung Cancer: Practical Advice for Clinicians 3rd European Lung Cancer Conference (ELCC) Geneva, Switzerland - “How should EGFR mutation status be evaluated?”

May 23 2012

Invited Speaker at the Marsden Annual Cancer Meeting, London - Molecular Pathology: Tissue is the issue

8-12 Septem 2012

Invited Speaker at the 24th European Congress of Pathology (Prague) -Predictive biomarkers in NSCLC in the pre­sent and the future; challenges and opportu­nities of a changing landscape

30-31 Octob 2012

Invited speaker at the 50th Anniversary Symposium on Molecular Pathology Symposium organized by the Royal College of Pathologist s of Great Britain and Ireland - Integrating genetics & histopathology, London

11December 2012

Invited Teaching Faculty at the first Molecular Pathology and Diagnosis of Cancer course (9-14 December 2012), organized by the Welcome Trust / Sanger Institute - “Tissue Molecular Diagnostics” and every year onwards

2013

20 April 2013

Lecture “Era of Molecular Targeted Therapy for Lung Cancer: The Role of Pathology” at the Expert Practice in Lung Cancer Annual Meeting in Paris, France

22 APRIL 2013

Lecture “Aspectos Moleculares del cáncer gástrico. Avances en la clasificación del cáncer gástrico” at the FÓRMULA II EN CÁNCER GÁSTRICO meeting in Madrid, Spain

26-30 May 2013

Chairperson of the Symposium “ECHOENDOSCOPIC FNAC. Toward a more personalized medicine” and lecture “Introduction: cytology and lung cancer – a new paradigm?”, at the 18th International Congress of Cytology, Paris (France)

2 September 2013

Co-chairmanship of the session “Cytology and molecular testing: What is effective?” and lecture “Personalised Medicine and Molecular Cytopathology: a Critical Appraisal ” - 25th European Congress of Pathology in Lisbon (Portugal)

31.10.–1.11.2013

Lecture: Molecular stratification of oesophago-gastric cancer. 2nd Translational Research Meeting of the EORTC GI-Group. University Hospital Carl Gustav Carus, Dresden, Germany.

November 2013

Lecture: What funders are looking for in a project involving tissue. Symposium by the Confederation of Cancer Biobanks, annual NCRI, Liverpool

2014

6 February 2014

Facultade de Medicina da Universidade de São Paulo: The Northern Ireland Molecular Pathology Laboratory – New insights in Hepatocellular Carcinoma and Clinical Sequencing in Molecular Diagnostics. São Paulo, Brazil

26-28 August 2014

Invited speaker at the International Congress of Pathology and Laboratory Medicine (ICPaLM), in Kuala Lumpur, Malaysia, to deliver several lectures

28 Septemb 2014

Invited Speaker: European Society of Medical Oncology satellite symposium on “Understanding the Multidisciplinary Focus for Improving Gastric Cancer Care”, to lecture on The Role of Pathology in Gastric Cancer Care, Madrid (Spain) .

2015

23 February 2015

Invited speaker to the Clínica Universitaria de Navarra: “Morpho-molecular Pathology: an Integrated Model for Diagnosis and Science”, Pamplona,

16-17 April 2015

Invited speaker at the Spanish Multidisciplinary Group for the Study of Cancer of the Digestive System (international meeting) to lecture: Advances in molecular classification of gastric cancer. Valencia, Spain

24 June 2015

Invited speaker: 8th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, to lecture “Training in Pathology – The Belfast Model”’, Dublin

6-8 of August 2015

Invited Speaker at the “II International Symposium on Personalized Medicine”, the Albert Einstein Research and Education Institute - “Next Generation Sequencing and Oncology“. São Paulo, (Brazil)

 

2016

27 June 2016

Invited Speaker at the Universitätsspital Basel to deliver the lecture: “Future perspectives in Molecular Pathology – Changing Pathology Practice, Basel Switzerland

4 October 2016

Keynote Lecture at the 40th European Congress of Cytology - More than a decade of Molecular Diagnostic Cytopathology : How do we Practice it, how do we Teach it?, Liverpool (UK)

21 October 2016

Invited Lecture at the The Gathering Around Cancer, Croke Park - Microsatellite Instability, broad genomic testing and tumour microenvironment in colorectal cancer: Practical aspects in Pathology practice and clinical relevance. Dublin. Ireland

17 November 2016

Keynote Lecture at the Annual Meeting of the International Academy of Pathology - Finnish Division – “Digital workflows in molecular pathology”, Helsinki (Finland)

 

2017

2 February 2017

Expert speaker at the Arab Health Congress, Dubai International Convention and Exhibition Centre., Dubai, UAE – Session “Leaders in Healthcare- Innovation in healthcare automation and technology”, talk - “Digital pathology workflows to deliver personalised medicine”

13 March 2017

Invited Lecture: Introduction to Molecular Pathology – what do we mean, what do you need to know, and why?  British Division of the International Academy of Pathology Molecular Pathology Study Day 

31 March 2017

Invited speaker - ‘‘Integrated Molecular Pathology and Translational Medicine’’, at the official launch of the Trinity Translational Medicine Institute – Trinity College Dublin

 

June 2017

Organizer – Biannual combines PathSoc/BDIAP meeting, Belfast The Waterfront

November 2017

Invited International Keynote speaker – Natinal Congress of Anantomic Pathology in Chile – Puerto Montt

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Fingerprint

Dive into the research topics where Manuel Salto-Tellez is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or